How much revenue does Sichuan Huiyu Pharmaceutical make?

Sichuan Huiyu Pharmaceutical reported 1.09 billion CNY in revenue for fiscal year 2024, up 18.0% from 927.08 million CNY in fiscal year 2023. In Q2 2025 revenue was 214.07 million CNY.

Where does Sichuan Huiyu Pharmaceutical make most of its revenue?

China: 85% of revenue by region in fiscal year 2024, followed by Overseas (15%).

What companies are similar to Sichuan Huiyu Pharmaceutical?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include InventisBio Co., Limited (688382.SS), Shanghai Yizhong Pharmaceutical Co., Ltd. (688091.SS), Jiangsu Yahong Meditech Co., Ltd. (688176.SS), Shouyao Holdings (Beijing) Co., Ltd. (688197.SS).

Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS) Stock

About Sichuan Huiyu Pharmaceutical Co., Ltd.

Sichuan Huiyu Pharmaceutical Co., Ltd. researches, develops, produces, and sells anti-tumor injection in China and internationally. It offers injection drug products, such as pemetrexed disodium, methrotrexate, docetaxel, azacitidine, oxaliplatin, cyclophosphamide, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, decitabine, palonosetron hydrochloride, plerixafor, levetiracetam co...

At a glance

Sichuan Huiyu Pharmaceutical reported revenue of 1.09 billion CNY for fiscal year 2024, up 18.0% from fiscal year 2023, and net income of 325.39 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 214.07 million CNY, down 26.1% from a year before. China was its largest region in fiscal year 2024, with 85% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.